日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Healthcare resource utilization and healthcare costs in patients with type 2 diabetes mellitus initiating sodium-glucose cotransporter 2 inhibitors vs dipeptidyl peptidase-4 inhibitors in Japan: A real-world administrative database analysis

日本2型糖尿病患者使用钠-葡萄糖协同转运蛋白2抑制剂与二肽基肽酶-4抑制剂治疗的医疗资源利用和医疗成本：一项基于真实世界行政数据库的分析

期刊:Journal of Diabetes Investigation
影响因子:3
doi:10.1111/jdi.14123
Kashiwagi, Atsunori; Shoji, Shingo; Kosakai, Yoshinori; Yoshinaga, Yoko; Rokuda, Mitsuhiro
糖尿病
代谢
发表日期：2024
文献求助 收藏

Cardiometabolic risk reductions in patients with type 2 diabetes mellitus newly treated with a sodium-glucose cotransporter 2 inhibitor versus a dipeptidyl peptidase-4 inhibitor: A real-world administrative database study in Japan

日本一项基于真实世界行政数据库的研究比较了新近接受钠-葡萄糖协同转运蛋白2抑制剂治疗的2型糖尿病患者与接受二肽基肽酶-4抑制剂治疗的患者在降低心血管代谢风险方面的差异。

期刊:Journal of Diabetes Investigation
影响因子:3
doi:10.1111/jdi.13952
Kashiwagi, Atsunori; Shoji, Shingo; Kosakai, Yoshinori; Koga, Tadashi; Asakawa, Keiko; Rokuda, Mitsuhiro
糖尿病
代谢
发表日期：2023
文献求助 收藏

Patient- and physician-reported outcomes from two phase 3 randomized studies (RAJ3 and RAJ4) of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis

两项针对亚洲类风湿性关节炎患者的peficitinib (ASP015K) 3期随机研究（RAJ3和RAJ4）的患者和医生报告结果

期刊:Arthritis Research & Therapy
影响因子:4.6
doi:10.1186/s13075-021-02590-z
Tanaka, Yoshiya; Takeuchi, Tsutomu; Izutsu, Hiroyuki; Kaneko, Yuichiro; Kato, Daisuke; Fukuda, Musashi; Rokuda, Mitsuhiro; Schultz, Neil M
关节炎
发表日期：2021
文献求助 收藏

Safety and Effectiveness of Peficitinib (ASP015K) in Patients with Rheumatoid Arthritis: Final Results (32 Months of Mean Peficitinib Treatment) From a Long-Term, Open-Label Extension Study in Japan, Korea, and Taiwan

培非替尼（ASP015K）治疗类风湿性关节炎患者的安全性和有效性：一项在日本、韩国和台湾开展的长期开放标签扩展研究的最终结果（平均培非替尼治疗32个月）

期刊:Rheumatology and Therapy
影响因子:2.9
doi:10.1007/s40744-021-00280-5
Takeuchi, Tsutomu; Tanaka, Yoshiya; Tanaka, Sakae; Kawakami, Atsushi; Song, Yeong-Wook; Chen, Yi-Hsing; Rokuda, Mitsuhiro; Izutsu, Hiroyuki; Ushijima, Satoshi; Kaneko, Yuichiro
关节炎
发表日期：2021
文献求助 收藏

Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan

培非替尼（ASP015K）治疗类风湿性关节炎患者的安全性和有效性：一项在日本、韩国和台湾开展的长期开放标签扩展研究的中期数据（平均培非替尼治疗时间为22.7个月）

期刊:Arthritis Research & Therapy
影响因子:4.6
doi:10.1186/s13075-020-2125-2
Takeuchi, Tsutomu; Tanaka, Yoshiya; Tanaka, Sakae; Kawakami, Atsushi; Song, Yeong-Wook; Chen, Yi-Hsing; Rokuda, Mitsuhiro; Izutsu, Hiroyuki; Ushijima, Satoshi; Kaneko, Yuichiro; Nakashima, Yoshihiro; Shiomi, Teruaki; Yamada, Emi
关节炎
发表日期：2020
文献求助 收藏

Correction to: Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan

更正：peficitinib (ASP015K) 在类风湿性关节炎患者中的安全性和有效性：来自日本、韩国和台湾一项长期开放标签扩展研究的中期数据（平均 peficitinib 治疗 22.7 个月）

期刊:Arthritis Research & Therapy
影响因子:4.6
doi:10.1186/s13075-020-02247-3
Takeuchi, Tsutomu; Tanaka, Yoshiya; Tanaka, Sakae; Kawakami, Atsushi; Song, Yeong-Wook; Chen, Yi-Hsing; Rokuda, Mitsuhiro; Izutsu, Hiroyuki; Ushijima, Satoshi; Kaneko, Yuichiro; Nakashima, Yoshihiro; Shiomi, Teruaki; Yamada, Emi
关节炎
发表日期：2020
文献求助 收藏

Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan

在日本开展的一项III期随机、双盲、安慰剂对照试验（RAJ4）结果显示，peficitinib（ASP015K）治疗对甲氨蝶呤反应不足的类风湿性关节炎患者的疗效和安全性

期刊:Annals of the Rheumatic Diseases
影响因子:20.6
doi:10.1136/annrheumdis-2019-215164
Takeuchi, Tsutomu; Tanaka, Yoshiya; Tanaka, Sakae; Kawakami, Atsushi; Iwasaki, Manabu; Katayama, Kou; Rokuda, Mitsuhiro; Izutsu, Hiroyuki; Ushijima, Satoshi; Kaneko, Yuichiro; Shiomi, Teruaki; Yamada, Emi; van der Heijde, Désirée
关节炎
发表日期：2019
文献求助 收藏

Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3)

佩菲替尼 (ASP015K) 治疗对传统 DMARD 反应不足的类风湿性关节炎患者的疗效和安全性：一项随机、双盲、安慰剂对照 III 期试验 (RAJ3)

期刊:Annals of the Rheumatic Diseases
影响因子:20.6
doi:10.1136/annrheumdis-2019-215163
Tanaka, Yoshiya; Takeuchi, Tsutomu; Tanaka, Sakae; Kawakami, Atsushi; Iwasaki, Manabu; Song, Yeong Wook; Chen, Yi-Hsing; Wei, James Cheng-Chung; Lee, Sang-Heon; Rokuda, Mitsuhiro; Izutsu, Hiroyuki; Ushijima, Satoshi; Kaneko, Yuichiro; Akazawa, Rio; Shiomi, Teruaki; Yamada, Emi
关节炎
发表日期：2019
文献求助 收藏

Functional characterization of two type III secretion systems of Vibrio parahaemolyticus

副溶血弧菌两种III型分泌系统的功能特征

期刊:Infection and Immunity
影响因子:2.9
doi:10.1128/IAI.72.11.6659-6665.2004
Kwon-Sam Park, Takahiro Ono, Mitsuhiro Rokuda, Myoung-Ho Jang, Kazuhisa Okada, Tetsuya Iida, Takeshi Honda
发表日期：2004
文献求助 收藏